A New Paradigm in Oncology and Age-Related Disease Therapeutics
The First A.I. Designed CAR-Targeted (CT) Nano-BioSphere
Technology for the Treatment of
Solid Tumors and Hereditary Disease
Solid Tumors and Age-Related Diseases
CT Nano-BioSpheres are innovative therapeutic agents that emulate the functions of T cells, Natural Killer cells, or macrophages. These targeted vesicles, derived from an allogeneic parent cell, house chimeric antigen receptors (CARs) and optional checkpoint inhibition tags. This unique design enables highly targeted and safe release of apoptotic proteins to diseased cells, offering a promising solution to the limitations of conventional CAR cellular therapies in treating a variety of diseases, including solid tumor cancers and age-related diseases.
Advancing Precision Medicine to New Levels
CAR-Targeted (CT) Nano-BioSphere Therapeutics
Introducing the CT Nano-BioSphere Therapeutic: Advancing Precision Medicine
​
At Caravan Biologix, our focus is on leveraging the CT Nano-BioSphere technology to address critical human diseases. Our therapeutic platform provides a versatile foundation for developing nearly unlimited differentials of CT Nano-BioSphere that can be tailored to treat different human diseases, demonstrating our dedication to advancing healthcare on multiple fronts.
​
In addition to developing our own pipeline of CT Nano-BioSphere drugs, a key aspect of our strategy involves collaborating with other biotech companies, offering our platform for the development of their own CT Nano-BioSphere driven pipelines. The out licensing of our platform technology can result in the production of standalone therapies or co-therapeutics alongside their existing medicines, showcasing our commitment to advancing healthcare through strategic partnerships and collaborations.
​
In addition to licensing, we are actively utilizing the CT Nano-BioSphere platform to develop our own therapeutic pipeline, meticulously designed to enhance human health and showcase the platform's full range of druggable properties. This strategic approach ensures that our research not only benefits our own pipeline but also contributes to the broader understanding and utilization of the CT Nano-BioSphere technology in the medical field.
​
CT Nano-BioSpheres are innovative drug candidates designed to emulate the functions of immune cells. Our CT Nano-BioSphere pipeline is focused on precision targeting of specific diseases, with a particular emphasis on cancer therapy. We are exploring the potential of releasing perforins, granzymes, and p53 to solid tumor cancers and senescent cells (longevity), offering a more effective alternative to cell-based treatments.
Properties Beyond Cellular CAR-Based Therapeutic Technologies
Immune
Silent
Multi-dosing Properties
Tumor-Honing
Migratory Tuning Capabilities
Ultra Low Cytotoxicity
Elimination of CRS
Superior Barrier Crossing
Organ Directed Treatment
Homogeneous and Low-Cost Manufacturing
Competitive Reproducibility
CT Nano-BioSphere
Enhanced Precision Immuno Therapy
Immune Silent
Our CT Nano-BioSpheres are derived
from HLA-silent and differentiated iPSCs
Biomarker
Targeting
We use advanced AI programming to select the best CARs based on Immunological Synapse quality
Tumor
Accessibility
The CT Nano-BioSphere is the optimal size to deeply penetrate solid tumors for maximum killing power
CRS
Prevention
With no genetic baggage or cytotoxic proteins, our CT Nano-BioSpheres vastly reduce the occurrence of cytokine storm
Cytokine
Control
Our proprietary upstream cellular activation process allows for the expression of any desired therapeutic peptide or nucleic acid
Barrier
Crossing
Our CT Nano-BioSpheres contain multiple properties that allow them to cross tissue barriers with unprecedented efficiency
Our Research Partners
Partnering
Contact Caravan Biologix to Build Your CT Nano-BioSphere Therapeutic Pipeline
Our robust partnering program can take your current therapeutic approach to new highly efficacious levels safer than other technologies.
​
